Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

British Journal of Dermatology

Volumn 174, Issue 5, 2016, Pages 985-995

  Ludbrook, V J ^a   Hicks, K J ^a   Hanrott, K E ^a   Patel, J S ^a   Binks, M H ^a   Wyres, M R ^b   Watson, J ^a   Wilson, P ^a   Simeoni, M ^a   Schifano, L A ^c   Reich, K ^d   Griffiths, C E M ^e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Stiefel Laboratories Inc   (United States)

^c GLAXOSMITHKLINE   (United States)

^d DERMATOLOGIKUM HAMBURG   (Germany)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SOLCITINIB; AZETIDINE DERIVATIVE; DERMATOLOGICAL AGENT; GSK2586184; JAK1 PROTEIN, HUMAN; JANUS KINASE 1; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENE EXPRESSION; HEADACHE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PETECHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN BIOPSY; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; URETER STONE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; GENETICS; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AZETIDINES; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION; HUMANS; JANUS KINASE 1; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84962763923     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14399     Document Type: Article

References (22)

1. Parisi R, Symmons DP, Griffiths CE, et al,. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
2. Kimball AB, Gladman D, Gelfand JM, et al,. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-42.
3. Mattei PL, Corey KC, Kimball AB,. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333-7.
4. Dalgard FJ, Gieler U, Tomas-Aragones L, et al,. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984-91.
5. Kim J, Krueger JG,. The immunopathogenesis of psoriasis. Dermatol Clin 2015; 33: 13-23.
6. Ihle JN, Witthuhn BA, Quelle FW, et al,. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994; 19: 222-7.
7. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
8. Michalak-Stoma A, Bartosinska J, Kowal M, et al,. Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers 2013; 35: 625-31.
9. Michalak-Stoma A, Pietrzak A, Szepietowski JC, et al,. Cytokine network in psoriasis revisited. Eur Cytokine Netw 2011; 22: 160-8.
10. Papp KA, Menter A, Strober B, et al,. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167: 668-77.
11. Menter A, Papp KA, Tan H, et al,. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. J Drugs Dermatol 2014; 13: 252-6.
12. Stein BL, Crispino JD, Moliterno AR,. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr Opin Oncol 2011; 23: 609-16.
13. van Vollenhoven RF,. Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol 2013; 25: 391-7.
14. Papp K, Pariser D, Catlin M, et al,. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 2015; 173: 767-76.
15. Punwani N, Scherle P, Flores R, et al,. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012; 67: 658-64.
16. GSK Clinical Study Register. Study ID 116439. Available at: http://www.gsk-clinicalstudyregister.com/study/116439#rs (last accessed 2 February 2016).
17. Hsu L, Armstrong AW,. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res 2014; 2014: 283617.
18. Ward AC, Touw I, Yoshimura A,. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000; 95: 19-29.
19. Gudjonsson JE, Ding J, Johnston A, et al,. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 2010a; 130: 1829-40.
20. Lebwohl M, Yeilding N, Szapary P, et al,. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63: 571-9.
21. Yao Y, Richman L, Morehouse C, et al,. Type I interferon: potential therapeutic target for psoriasis? PLoS ONE 2008; 3: e2737.
22. Oestreicher JL, Walters IB, Kikuchi T, et al,. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001; 1: 272-87.